Background: Anti-phospholipid (aPL) antibodies (Abs) frequently found in the plasma of patients with systemic lupus erythematosus (SLE) have been associated with thrombotic complications. Our aim was to clarify the roles in thrombosis of aPL Abs that react with complexes of phospholipids and plasma proteins such as ␤ 2 -glycoprotein I (␤ 2 -GPI), prothrombin, protein C, protein S, and annexin V. Methods: We determined the prevalence of aPL Abs to various phospholipid-binding plasma proteins in SLE patients with arterial thrombosis (30 cases), venous thrombosis (19 cases), thrombocytopenia (14 cases), fetal loss (14 cases), and patients without complications (91 cases). The aPL Abs were measured by an ELISA system in which human plasma proteins (␤ 2 -GPI, prothrombin, protein C, protein S, and annexin V) were immobilized on ␥-irradiated or plain polystyrene plates. Results: All types of aPL Abs were frequently observed in the patients with SLE when ␥-irradiated polystyrene plates were used (51 of 168 cases positive for anti-␤ 2 -GPI, 94 of 168 cases positive for anti-prothrombin, 36 of 168 cases positive for anti-protein C, 47 of 168 cases positive for anti-protein S, and 50 of 168 cases positive for anti-annexin V), whereas no Abs to these plasma
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sis, thrombocytopenia, and fetal loss in these patients are unclear.
SLE patients with both aCL and LA have a high prevalence of arterial and venous thrombosis and thrombocytopenia (21, 22 ) , with an inverse correlation between platelet count and aCL concentrations in LA-positive patients (22 ) . The IgG fraction purified from plasma from SLE patients containing both aCL and LA enhanced the platelet activation triggered by ADP, whereas IgG from plasma containing either aCL or LA had little or no effect (23 ) . These findings suggest that aCL and LA may cooperate to promote platelet activation and participate in the pathogenesis of arterial thrombosis in patients with SLE.
In 1990, three groups of investigators reported simultaneously that aCL was not directed against anionic phospholipids, but it recognized plasma protein ␤ 2 -glycoprotein I (␤ 2 -GPI) with an affinity for anionic phospholipid surfaces (24 -26 ) . The epitope for aCL expressed on ␤ 2 -GPI changed conformationally by interaction with negatively charged phospholipids or with an oxygen-substituted solid surface (27) (28) (29) (30) (31) , whereas LA recognized human prothrombin bound to anionic phospholipids (32) (33) (34) . Although ␤ 2 -GPI and prothrombin are accepted antigens of aPL Abs (35) (36) (37) (38) , aPL Abs may also recognize different complexes of anionic phospholipids and a variety of plasma proteins, including protein C, protein S, and annexin V (39 -40 ) .
In the present study, we examined the prevalence of IgG Abs against phospholipid-binding plasma proteins (␤ 2 -GPI, prothrombin, protein C, protein S, and annexin V) in patients with SLE. Recent studies have indicated that Abs to ␤ 2 -GPI and prothrombin do not recognize the native forms of ␤ 2 -GPI and prothrombin in plasma, but they do recognize conformationally changed structures of ␤ 2 -GPI and prothrombin after binding to negatively charged phospholipids (26 -28, 32, 33, 40 ) . Moreover, the conformational changes of ␤ 2 -GPI and prothrombin were recently found even when these proteins were bound to the anionic surface of a ␥-irradiated polystyrene plate in the absence of phospholipids (29, 31, 35, 40 ) . Therefore, we used an ELISA system specific for detecting the aPL Abs, in which ␤ 2 -GPI, prothrombin, protein C, protein S, and annexin V were directly immobilized on either ␥-irradiated polystyrene plates or plain polystyrene plates, and we investigated the relationships between these Abs and thrombotic and thrombocytopenic complications.
Materials and Methods patients
We studied plasma samples from 168 patients (159 females, 9 males; 10 -75 years; mean, 40 years) with SLE. Diagnosis of SLE was made according to the revised criteria of the American Rheumatism Association. Clinical history indicated thrombotic complications in 49 of the SLE patients: cerebral infarction (18 patients), pulmonary infarction (3 patients), transient cerebral ischemic attack (2 patients), femoral artery thrombosis (5 patients), foot and finger artery thrombosis (2 patients), pulmonary embolism (3 patients), deep vein thrombosis (14 patients), and renal vein thrombosis (2 patients). All of the thrombotic complications had been documented by venography, arteriography, angiography, Doppler ultrasound, and/or computed tomography scan. Of the 168 SLE patients, 38 had thrombocytopenia (platelet count, Ͻ100 ϫ 10 9 /L), 14 of whom had only thrombocytopenia, and 24 of whom had both thrombocytopenia and thrombosis. Thrombocytopenia was defined by a platelet count of Ͻ100 ϫ 10 9 /L measured on at least two separate occasions. We defined fetal loss, seen in 14 patients, as abortion, stillbirth, or dead fetus more than twice during our clinical observation. As controls, we also studied 80 plasma samples from healthy volunteers. Blood samples were collected in evacuated tubes (total volume, 5.0 mL; SEKISUI MEDICAL) containing 0.5 mL of 31.3 g/L trisodium citrate (Na 3 C 6 H 5 O 7 ⅐ 2 H 2 O) and centrifuged at 2800g for 10 min.
detection of aCL and la aCL was measured by ELISA as reported previously (21, 22 ) . The cutoff for aCL Abs (398.0 milliabsorbance units) was reported previously (21, 22 ) . The LA activity was detected with both the tissue thromboplastin inhibition test and a commercial reagent set (STACLOT LA test; Diagnostica Stago) as described previously (21, 22 ) . measurement of Abs to phospholipid-binding plasma proteins ␥-Irradiated polystyrene plates (Maxi-Sorp Nunc-Immunoplates; Kamstrup) or plain polystyrene plates (Immulon-1; Dynatec) were coated overnight at 4°C with 50 L per well of ␤ 2 -GPI, prothrombin, protein C, protein S (Diagnostica Stago), or annexin V (Sigma), each suspended at a concentration of 10 mg/L in Tris-buffered saline (TBS; 50 mmol/L Tris-HCl, 0.1 mol/L NaCl, pH 7.4). The wells were blocked with 50 L of TBS containing 10 g/L bovine serum albumin (Sigma) for 60 min at room temperature and then washed three times with TBS containing 1 mL/L Tween 20. A 50-L plasma sample (diluted 101-fold with 10 mL/L bovine serum albumin in TBS containing 1 mL/L Tween 20) was added to each well. After 60 min of incubation at room temperature, the wells were washed with TBS-Tween. Horseradish peroxidase-conjugated goat anti-human IgG (␥-chain specific; cat. no. A-2290) or IgM (-chain specific; cat. no. A-4290) F(abЈ) 2 fragment of affinity-isolated Ab (Sigma) was used, and the color was developed by means of tetramethylbenzidine solution (Moss, Inc). The absorbance was measured at 450 nm. The absorbance of blank wells (i.e., coated only with TBS) was subtracted from the absorbance in the antigen-coated wells to account for nonspecific binding. We studied the concentrations of these aPL Abs in 80 healthy control subjects. The mean ϩ 3 SD of each Ab in controls was chosen as the cutoff point. The cutoff values for anti-␤ 2 -GPI, anti-prothrombin, anti-protein C, antiprotein S, and anti-annexin V Abs were 392.1, 500.8, 499.2, Clinical Chemistry 47, No. 6, 2001 500.0, and 299.8 milliabsorbance units, respectively. Monoclonal anti-human ␤ 2 -GPI, anti-human prothrombin, anti-human protein C, anti-human protein S (BML), or anti-human annexin V (KBC) were used in each plate as a positive control, and selected control plasma samples were used as a negative control.
statistical analysis
Pearson's correlation coefficients (r) were calculated for pairs of Abs. The nonparametric Mann-Whitney test was used to compare the concentrations of Abs among groups. Fisher's exact probability test was used to evaluate the association between the prevalence of each Ab and clinical complications. As an approximation of the relative risk, the odds ratio (OR) was calculated for several putative risk factors by multivariate logistic regression analysis with the statistical program Stat Flex (Ver. 4.2; Artech Inc.). The variable that achieved statistical significance in the first analysis was tested in a second analysis by multivariate logistic regression analysis. An OR was considered statistically significant when the lower limit of the 95% confidence interval (CI) was Ͼ1.0. In the multivariate logistic regression analysis, a P value Ͻ0.05 was considered statistically significant for risk factors.
Results prevalence of Abs to ␤ 2 -gpi, prothrombin, protein c, protein s, and annexin v in patients with sle When ␥-irradiated polystyrene plates were used, the prevalence of Abs to each of the five plasma proteins in the 168 patients with SLE was 21-56% (Table 1) . In contrast, none of these Abs was detected in 168 plasma samples from the SLE patients when plain polystyrene plates were used.
relationship of la with Abs to ␤ 2 -gpi, prothrombin, protein c, protein s, and annexin v in sle patients LA activity was detected in 83 of the 168 cases (49%) with the use of both the tissue thromboplastin inhibition and STACLOT LA tests. When we examined the prevalence of each IgG Ab in LA-positive (n ϭ 83) and LA-negative (n ϭ 85) patients, IgG Abs to prothrombin and ␤ 2 -GPI were detected in LA-positive patients at a higher rate than in LA-negative patients (71% vs 42% for anti-prothrombin Abs, P Ͻ0.0002; 49% vs 13% for anti-␤ 2 -GPI Abs, P Ͻ0.0001). On the other hand, the prevalences of IgG Abs to protein C, protein S, and annexin V were not statistically different between patients with and without LA (28% vs 15% for anti-protein C Abs; 31% vs 25% for anti-protein S Abs; 30% vs 28% for anti-annexin V Abs; Fig. 1 ).
We also studied IgM Abs to prothrombin and ␤ 2 -GPI. The prevalence of IgM Abs to prothrombin was significantly higher in LA-positive patients than in LA-negative patients (19% vs 2.4%; P Ͻ0.0004), whereas there was no significant difference in the prevalence of IgM Abs to ␤ 2 -GPI between LA-positive and -negative groups (9.6% vs 5.9%; data not shown).
correlation between the concentrations of Abs to ␤ 2 -gpi, prothrombin, protein c, protein s, and annexin v in the patients with sle
In the plasma of 168 SLE patients, a highly significant correlation was found between the concentrations of aCL and IgG Abs to ␤ 2 -GPI (r ϭ 0.86; P Ͻ0.001; Fig. 2A) . However, the concentrations of aCL showed no significant correlation with those of IgG Abs to prothrombin (r ϭ 0.23), protein C (r ϭ 0.12), protein S (r ϭ 0.09), or annexin V (r ϭ 0.10; data not shown). In addition, there was no significant correlation between anti-␤ 2 -GPI Abs and anti-prothrombin (r ϭ 0.26) Abs, anti-protein C Abs (r ϭ 0.21), anti-protein S Abs (r ϭ 0.06), or anti-annexin V Abs (r ϭ 0.17; data not shown). The concentrations of IgG Abs to prothrombin correlated significantly with the Fig. 1 . Prevalence of anti-␤ 2 -GPI, anti-prothrombin, anti-protein C, anti-protein S, and anti-annexin V Abs in the SLE patients with (n ϭ 83) or without (n ϭ 85) LA activity.
‫,ءءء‬ P Ͻ0.0002; ‫,ءء‬ P Ͻ0.0001; N.S., not significant. concentrations of IgG Abs to protein C (r ϭ 0.61; P Ͻ0.001; Fig. 2B ), as well as to protein S (r ϭ 0.48; P Ͻ0.01; Fig. 2C ). IgG Abs to protein C were significantly correlated with protein S (r ϭ 0.66; P Ͻ0.001; Fig. 2D ). There were no significant correlations between the concentrations of IgG Abs to the following combinations: prothrombin and annexin V (r ϭ 0.18), protein C and annexin V (r ϭ 0.33), and protein S and annexin V (r ϭ 0.18; data not shown).
concentrations of aCL and IgG Abs to ␤ 2 -gpi, prothrombin, protein c, protein s, and annexin v in sle patients with or without complications
The 168 SLE patients were divided into five groups according to their complications: arterial thrombosis (30 cases), venous thrombosis (19 cases), thrombocytopenia without thrombosis (14 cases), fetal loss (14 cases), and no thrombotic or thrombocytopenic complications (91 cases). The concentrations of each Ab were examined. As shown in Fig. 3 , the concentrations of aCL were significantly higher in the patients with arterial thrombosis (1740 Ϯ 196, mean Ϯ SE; P Ͻ0.0001), venous thrombosis (998 Ϯ 229; P Ͻ0.0005), and thrombocytopenia (774 Ϯ 164; P Ͻ0.002) than in those without complications (297 Ϯ 37). The concentrations of ␤ 2 -GPI IgG Abs were increased significantly in the patients with arterial thrombosis (1076 Ϯ 140; P Ͻ0.0001) and venous thrombosis (591 Ϯ 132; P Ͻ0.0005), but not in the patients with thrombocytopenia (276 Ϯ 47), when compared with those in the patients without complications (234 Ϯ 26). The mean anti-prothrombin IgG Ab concentration was higher in the patients with arterial thrombosis (809 Ϯ 43; P Ͻ0.0001), venous thrombosis (935 Ϯ 98; P Ͻ0.0001), and thrombocytopenia (630 Ϯ 61; P Ͻ0.04) than in those without complications (419 Ϯ 49), as in the case of aCL. The concentrations of IgG Abs to protein C and protein S were significantly higher in the patients with venous thrombosis (600 Ϯ 68 for anti-protein C, P Ͻ0.0001; 901 Ϯ 98 for anti-protein S, P Ͻ0.0001) than in the patients without complications (anti-protein C, 315 Ϯ 146; anti-protein S, 372 Ϯ 306), but no statistical difference was observed in the patients with arterial thrombosis (anti-protein C, 375 Ϯ 31; anti-protein S, 409 Ϯ 37), or thrombocytopenia (anti-protein C, 288 Ϯ 30; anti-protein S, 350 Ϯ 51). Horizontal and vertical lines represent the upper decision limits (i.e., the mean ϩ 3 SD of the value for the healthy control group). Statistical analysis was performed using Pearson's correlation coefficient (r).
Anti-annexin V IgG Abs were higher in the patients with venous thrombosis (380 Ϯ 61; P Ͻ0.001) and fetal loss (280 Ϯ 31; P Ͻ0.02) as compared with the Abs in the patients without complications (189 Ϯ 11). Thus, among aCL, anti-␤ 2 -GPI, anti-prothrombin, anti-protein C, antiprotein S, and anti-annexin V Abs, only anti-annexin V Abs were significantly higher in the patients with fetal loss.
prevalence of la, aCL, and IgG Abs to ␤ 2 -gpi, prothrombin, protein c, protein s, and annexin v in sle patients with or without complications LA, aCL, and anti-prothrombin Abs (Fig. 4) were detected more in the patients with arterial thrombosis (LA, 93%; aCL, 83%; anti-prothrombin, 97%), venous thrombosis (LA, 79%; aCL, 63%; anti-prothrombin, 95%), and thrombocytopenia (LA, 64%; aCL, 57%; anti-prothrombin, 71%) than in patients without complications (LA, 29%; aCL, 19%; anti-prothrombin, 37%). There were no statistical differences in the prevalence of LA, aCL, and anti-prothrombin Abs among the patients with arterial thrombosis, venous thrombosis, and thrombocytopenia. On the contrary, the prevalence of anti-␤ 2 -GPI Abs was significantly higher in patients with arterial thrombosis (80%; P Ͻ0.01) than in those with venous thrombosis (42%) or thrombocytopenia (21%). Furthermore, we noted that the prevalences of anti-protein C and anti-protein S Abs were significantly higher in patients with venous thrombosis (68% for anti-protein C, P Ͻ0.002; 95% for anti-protein S, P Ͻ0.0001) than in those with arterial thrombosis (23% and 27%, respectively) or thrombocytopenia (0% and 21%, respectively). Interestingly, the prevalence of anti-annexin V Abs was higher in patients with fetal loss (64%) than in the patients without complications (18%; P Ͻ0.0001; Fig. 4) .
multivariate logistic regression analysis
The results of the multivariate logistic regression analysis of risk factors for arterial thrombosis, venous thrombosis, or fetal loss are shown in Table 2 . In this analysis, all of the values are analyzed as positive or negative, irrespective of the concentrations of Abs. Both anti-␤ 2 -GPI Abs and anti-prothrombin Abs were significant risk factors for arterial thrombosis (ORs, 8.8 and 14.5; 95% CIs, 3.2-25 and 1.8 -116 for anti-␤ 2 -GPI and anti-prothrombin, respectively), but not for venous thrombosis (ORs, 0.80 and 2.9; 95% CIs, 0.22-3.0 and 0.24 -34 for anti-␤ 2 -GPI and anti-prothrombin, respectively). On the contrary, the presence of The concentrations of aCL, anti-␤ 2 -GPI, anti-prothrombin, anti-protein C, anti-protein S, and anti-annexin V Abs were measured in the five populations of SLE patients: arterial thrombosis (30 cases), venous thrombosis (19 cases), thrombocytopenia without thrombosis (14 cases), fetal loss (14 cases), and patients without thrombotic and/or thrombocytopenic complications (91 cases). Gray boxes represent Ϯ 3 SD. Statistical analysis was performed by using the nonparametric Mann-Whitney test. ‫,ءءء‬ P Ͻ0.001; ‫,ءء‬ P Ͻ0.01; ‫,ء‬ P Ͻ0.05; N.S., not significant.
anti-protein S Abs was a significant risk factor for venous thrombosis (OR, 30.4; 95% CI, 3.3-281), but not for arterial thrombosis (OR, 0.30; 95% CI, 0.09 -0.98). The presence of anti-protein C Abs failed to be a significant risk factor for either arterial (OR, 0.86; 95% CI, 0.25-2.9) or venous (OR, 3.1; 95% CI, 0.88 -11) thrombosis in the patients with SLE. The only significant risk factor for fetal loss was the presence of anti-annexin V Abs (OR, 5.9; 95% CI, 1.4 -14.8).
Discussion
We designed an ELISA system specific for detecting the aPL Abs reactive with conformationally changed structures of ␤ 2 -GPI, prothrombin, protein C, protein S, and annexin V. In our ELISA system, IgG Abs to ␤ 2 -GPI, prothrombin, protein C, protein S, or annexin V were detected only when ␥-irradiated polystyrene plates were used in place of plain polystyrene plates. Because there was no significant difference in the amount of immobilized antigens in the plain and ␥-irradiated ELISA plates, we suggest that all of the aPL Abs found in patients with SLE are specific for a conformationally changed epitope(s) of each plasma protein.
In accordance with previous findings, the concentration and prevalence of LA and aCL were significantly higher in the patients with arterial thrombosis, venous thrombosis, or thrombocytopenia than in those without complications (21) (22) (23) . The prevalence and concentrations of anti-␤ 2 -GPI Abs were increased in the patients with arterial thrombosis and venous thrombosis but not significantly increased in the patients with thrombocytopenia. The findings that aCL was significantly increased in the thrombocytopenic patients suggests that thrombocytopenia may be associated with aPL Abs. However, aPL Abs detected by the aCL ELISA assay may be different from anti-␤ 2 -GPI Abs. In fact, although a significant correlation was observed between the concentrations of aCL detected by the standard ELISA and anti-␤ 2 -GPI Abs by use of a specific ELISA system ( Fig. 2A) , 22 (34%) of the 65 aCL-positive patients had no anti-␤ 2 -GPI Abs. These findings raise the possibility that the aCL ELISA may also detect Abs that are reactive with some components of human plasma or bovine serum proteins bound to the cardiolipin-coated wells. Indeed, of these 22 aCL-positive patients without anti-␤ 2 -GPI Abs, 5 had anti-prothrombin The prevalences of LA, aCL, anti-␤ 2 -GPI, anti-prothrombin, anti-protein C, antiprotein S, and anti-annexin V Abs found in the five populations of SLE patients, i.e., arterial thrombosis (30 cases), venous thrombosis (19 cases), thrombocytopenia without thrombosis (14 cases), fetal loss (14 cases), and patients without thrombotic and/or thrombocytopenic complications (91 cases), are shown. Results were regarded as positive when the absorbance exceeded mean ϩ3 SD of the control-group value. Statistical analysis was performed using Fisher's exact probability test. ‫,ءءء‬ P Ͻ0.001; ‫,ءء‬ P Ͻ0.01; ‫,ء‬ P Ͻ0.05. Abs; 2 had both anti-prothrombin and anti-protein S Abs; 5 had Abs to each of prothrombin, protein C, and protein S; and 10 had no Abs. Anti-prothrombin Abs were detected at high concentrations in the SLE patients with arterial thrombosis, as well as in those with venous thrombosis or thrombocytopenia, suggesting that anti-prothrombin Abs may not be specific for each of these complications. On the contrary, both the concentrations and the prevalences of antiprotein C and anti-protein S Abs were significantly higher in the patients with venous thrombosis than in those with arterial thrombosis, thrombocytopenia, or in subjects without complications, whereas the prevalence of anti-␤ 2 -GPI Abs was significantly higher in patients with arterial thrombosis than in those with venous thrombosis. Thus, anti-protein C and/or anti-protein S Abs and anti-␤ 2 -GPI Abs may play a differential role in the occurrence of thrombotic complications, anti-protein C and/or antiprotein S Abs may be associated primarily with venous thrombosis, and anti-␤ 2 -GPI Abs may be associated primarily with arterial thrombosis.
The concentration and prevalence of anti-annexin V Abs were significantly increased in SLE patients with venous thrombosis or fetal loss. In the case of venous thrombosis, 11 of the 19 SLE patients had anti-annexin V Abs, and 9 of these 11 anti-annexin V-positive patients had both anti-protein C and anti-protein S Abs. On the other hand, 9 of the 14 SLE patients with fetal loss had anti-annexin V Abs, but none of these patients showed both anti-protein C and anti-protein S Abs. These results suggest that anti-annexin V Abs might be closely related to fetal loss and that the combined effects of anti-annexin V, anti-protein C, and anti-protein S Abs might play a role in the pathogenesis of venous thrombosis.
The multivariate logistic regression analysis confirmed that the presence of anti-␤ 2 -GPI and anti-prothrombin Abs is an important risk factor for arterial thrombosis. Furthermore, it confirmed that the presence of antiprotein S Abs is a strong risk factor for venous thrombosis. As mentioned above, the prevalence of anti-protein C Abs was also higher in patients with venous thrombosis than in patients with other complications, but it is not an important risk factor for venous thrombosis as indicated by the multivariate logistic regression analysis. This analysis also indicates that only the presence of anti-annexin V Abs is an important risk factor for fetal loss.
Anti-␤ 2 -GPI Abs were reported to be associated with arterial and venous thrombosis and fetal loss in patients with SLE (41) (42) (43) , and anti-prothrombin Abs were reported to be associated with venous thrombosis (42, 44, 45 ) . In our study, both the concentrations and prevalences of anti-␤ 2 -GPI and anti-prothrombin Abs were significantly higher in the patients with arterial thrombosis and venous thrombosis than in those without complications. Judging from these results, anti-␤ 2 -GPI and anti-prothrombin Abs seemed associated with both arterial and venous thrombosis. However, multivariate logistic regression analysis of anti-protein C, anti-protein S, and anti-annexin V Abs in addition to anti-␤ 2 -GPI and anti-prothrombin Abs indicated that the presence of anti-␤ 2 -GPI and anti-prothrombin Abs was not a significant risk factor for venous thrombosis because the vast majority of the patients who had anti-␤ 2 -GPI and anti-prothrombin Abs without anti-protein S Abs did not have venous thrombosis. Recently, it was also reported that LA is the strongest risk factor for both arterial and venous thrombosis in patients with SLE (41 ) . As mentioned, LA activity can be produced by anti-␤ 2 -GPI and/or antiprothrombin Abs. We agree with Horbach et al. (41 ) that LA is a strong risk factor for arterial thrombosis because our results confirmed that both anti-␤ 2 -GPI and antiprothrombin Abs were significant risk factors for arterial thrombosis. However, our multivariate logistic regression analysis raises questions about the relationship between LA and venous thrombosis.
In summary, aPL Abs against phospholipid-bound proteins were present in the patients with SLE, and some aPL Abs, alone or in combination, may be associated with the pathogenesis of arterial and venous thrombosis and fetal loss.
